Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature

BJU Int. 2017 Oct;120(4):464-467. doi: 10.1111/bju.13862. Epub 2017 May 3.

Abstract

Active surveillance (AS) is an increasingly prevalent treatment choice for low grade prostate cancer. Eligibility criteria for AS are varied and it is unclear if family history of prostate cancer should be used as an exclusion criterion when considering men for AS. To determine whether family history plays a significant role in the progression of prostate cancer for men undergoing active surveillance, PubMed searches of 'family history and prostate cancer', 'family history and prostate cancer progression' and 'factors of prostate cancer progression' were used to identify research publications about the relationship between family history and prostate cancer progression. These searches generated 536 papers that were screened and reviewed. Six publications were ultimately included in this analysis. Review of the six publications suggests that family history does not increase the risk of prostate cancer progression, whilst a subgroup analysis in one study found that family history increases the risk of prostate cancer progression only in African-Americans. A family history of prostate cancer does not appear to increase a patient's risk of having more aggressive prostate cancer and is therefore unlikely to be an important factor in determining eligibility for AS. Further studies are needed to better understand the relationship between race, family history, and eligibility for AS.

Keywords: #PCSM; #ProstateCancer; active surveillance; family history.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Aged
  • Early Detection of Cancer / methods*
  • Genetic Predisposition to Disease / epidemiology*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Observational Studies as Topic
  • Patient Selection
  • Pedigree
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / therapy
  • Risk Assessment
  • United States / epidemiology
  • Watchful Waiting*

Substances

  • Prostate-Specific Antigen